TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2764537

Group type: EXPERIMENTAL
Intervention: Moxalactam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cefoperazone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cefotetan
Number of subjects: 0
Study: 939070

Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Sotalol with diuretic
Number of subjects: 23
Study: 31773765

Group type: EXPERIMENTAL
Intervention: Plasmakinetic resection of the prostate (PKRP)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Plasma button transurethral vapour enucleation of the prostate (PVEP)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Comparison of PVEP and PKRP
Number of subjects: 101
Study: 30910592

Group type: EXPERIMENTAL
Intervention: Osimertinib combined with chloroquine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Osimertinib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhibition of autophagy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Knockdown of Beclin-1
Number of subjects: 0
Study: 30350258

Group type: EXPERIMENTAL
Intervention: Out-of-home physical activity measured by accelerometer and physical activity diary.
Number of subjects: 334

Group type: COMPARATOR
Intervention: Social isolation measured using the Lubben Social Network Scale (LSNS-6).
Number of subjects: 334
Study: 27200503

Group type: EXPERIMENTAL
Intervention: Metreleptin (0.01, 0.1 and 0.3 mg per kg body weight) administered once in a 1-day-long trial
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Metreleptin (0.08 and/or 0.12 mg kg(‐1)) administered for 16 weeks
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo administered for 16 weeks
Number of subjects: 33
Study: 24369178

Group type: EXPERIMENTAL
Intervention: Parental Self-Efficacy (PSE) instrument for dietary and physical activity behaviors
Number of subjects: 162
Study: 23146150

Group type: EXPERIMENTAL
Intervention: Scopolamine hydrobromide (1 mg/d)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 20430601

Group type: EXPERIMENTAL
Intervention: Ciclesonide 80 microg once daily
Number of subjects: 480

Group type: COMPARATOR
Intervention: Fluticasone propionate 100 microg twice daily
Number of subjects: 480
Study: 18043104

Group type: EXPERIMENTAL
Intervention: Argon plasma coagulation (APC)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Surveillance
Number of subjects: 58
Study: 16086757

Group type: EXPERIMENTAL
Intervention: Iontophoresis with surfactant pretreatment (3-h application at 250 microA cm(‐2))
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Iontophoresis alone
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (passive treatments)
Number of subjects: 24
Study: 11850863

Group type: EXPERIMENTAL
Intervention: 23-valent polysaccharide pneumococcal vaccine
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 10597806

Group type: EXPERIMENTAL
Intervention: Medially linked KAFOs
Number of subjects: 9

Group type: COMPARATOR
Intervention: Unlinked KAFOs
Number of subjects: 9
Study: 7487465

Group type: EXPERIMENTAL
Intervention: Intravenous ganciclovir during ALA therapy (group 1)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No prophylaxis for CMV disease (group 2)
Number of subjects: 40
Study: 1766705

Group type: EXPERIMENTAL
Intervention: Erythromycin-sulfisoxazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cefaclor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6127719

Group type: EXPERIMENTAL
Intervention: ipratropium bromide (160 micrograms daily)
Number of subjects: 12

Group type: COMPARATOR
Intervention: thiazinamium methyl sulphate (900 mg daily)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: ipratropium bromide
Number of subjects: 12

Group type: COMPARATOR
Intervention: thiazinamium methyl sulphate
Number of subjects: 12
Study: 30797041

Group type: EXPERIMENTAL
Intervention: Exercise and lifestyle intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 0
Study: 27814302

Group type: EXPERIMENTAL
Intervention: Stimulant medication (dosage titrated by physician)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 25896973

Group type: EXPERIMENTAL
Intervention: Molecular analysis for actionable genomic data
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Tumor biopsy and archived tumor samples collection
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Screening for molecular targets
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Performance status assessment
Number of subjects: 93
Study: 25010541

Group type: EXPERIMENTAL
Intervention: Microhybrid composite with antibacterial system
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Nanohybrid composite
Number of subjects: 9

Group type: COMPARATOR
Intervention: Amalgam
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (non-restored dentine samples)
Number of subjects: 9
Study: 22100906

Group type: EXPERIMENTAL
Intervention: gemcitabine plus weight-adjusted dalteparin (WAD) for 12 weeks
Number of subjects: 123

Group type: COMPARATOR
Intervention: gemcitabine
Number of subjects: 123
Study: 20558428

Group type: COMPARATOR
Intervention: Bimatoprost 0.03%
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03% + Dorzolamide 2%
Number of subjects: 25
Study: 17335691

Group type: EXPERIMENTAL
Intervention: Myeloid growth factors (MGFs) used at varied schedules, doses, and durations differing from FDA approved prescribing information.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Myeloid growth factors (MGFs) administered on the same day as chemotherapy.
Number of subjects: 0
Study: 16291353

Group type: EXPERIMENTAL
Intervention: Hood (1.5 mg epinephrine in 4 mL saline [3%])
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Mask (1.5 mg epinephrine in 4 mL saline [3%])
Number of subjects: 49

Group type: COMPARATOR
Intervention: Hood
Number of subjects: 49

Group type: COMPARATOR
Intervention: Mask
Number of subjects: 49

Group type: COMPARATOR
Intervention: Indifferent
Number of subjects: 49
Study: 12406071

Group type: EXPERIMENTAL
Intervention: Whole-blood point-of-care testing (POCT) monitor (CoaguChek)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Hospital laboratory coagulometer prothrombin time (PT) testing
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Patient satisfaction with community POCT monitoring
Number of subjects: 46
Study: 10460118

Group type: EXPERIMENTAL
Intervention: Physiotherapy interventions (walking, standing balance, upper limb movement pattern)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Occupational therapy interventions (physical function, social and leisure activities, other)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Median treatment time for a session
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Variability in treatment delivery
Number of subjects: 89
Study: 7528271

Group type: EXPERIMENTAL
Intervention: ICE chemotherapy with G‐CSF
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Cohort 1 (n = 6) treated every 3 weeks
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Cohort 2 (n = 7) treated every 2 weeks
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Cohort 3 (n = 12) treated every 2 weeks
Number of subjects: 25
Study: 2381617

Group type: EXPERIMENTAL
Intervention: 2% clindamycin cream
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Lower concentrations of clindamycin cream (0.1% and 1%)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 67
Study: 7053123

Group type: EXPERIMENTAL
Intervention: Prophylactic ventilation
Number of subjects: 35

Group type: COMPARATOR
Intervention: Early extubation
Number of subjects: 35
Study: 30667337

Group type: EXPERIMENTAL
Intervention: Robotic antenna placement
Number of subjects: 31

Group type: COMPARATOR
Intervention: Freehand antenna placement
Number of subjects: 31
Study: 28778854

Group type: EXPERIMENTAL
Intervention: Enhanced personal health record only
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Patient navigator only
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Both enhanced personal health record and patient navigator
Number of subjects: 209

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 209
Study: 26381275

Group type: EXPERIMENTAL
Intervention: Ketoconazole (150 mg oral dose of crizotinib)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rifampin (250 mg oral dose of crizotinib)
Number of subjects: 0
Study: 23224127

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB) early treatment (IVB1)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Intravitreal triamcinolone (IVT) early treatment (IVT1)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB) late treatment (IVB2)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Intravitreal triamcinolone (IVT) late treatment (IVT2)
Number of subjects: 65
Study: 18165205

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo (other drug than spironolactone)
Number of subjects: 117
Study: 15493232

Group type: EXPERIMENTAL
Intervention: Code-based classroom instruction with a supplemental maintenance intervention
Number of subjects: 59

Group type: COMPARATOR
Intervention: Only code-based classroom instruction
Number of subjects: 59
Study: 10718784

Group type: EXPERIMENTAL
Intervention: Activated charcoal (25 g in 200 ml water)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Gastric lavage
Number of subjects: 9

Group type: COMPARATOR
Intervention: Water (200 ml) (control)
Number of subjects: 9
Study: 9177508

Group type: COMPARATOR
Intervention: Endoscopic variceal ligation (EVL) alone
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Combination of endoscopic variceal ligation (EVL) and endoscopic sclerotherapy (EST)
Number of subjects: 50
Study: 8415265

Group type: EXPERIMENTAL
Intervention: Budesonide forte aerosol Polfa, 200 micrograms four times daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: COMPARATOR
Intervention: Foreign made analogue
Number of subjects: 30
Study: 3537898

Group type: EXPERIMENTAL
Intervention: Powdered ginger root (Zingiber officinale)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31739249

Group type: EXPERIMENTAL
Intervention: Detection Engagement and Savoring Positivity (DESP) task
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control condition (placebo)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control condition (excluding savoring)
Number of subjects: 92
Study: 30592302

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 848

Group type: COMPARATOR
Intervention: Sham Acupuncture
Number of subjects: 848
Study: 28700282

Group type: EXPERIMENTAL
Intervention: Easyfour®-TT
Number of subjects: 244

Group type: COMPARATOR
Intervention: Quadrovax®
Number of subjects: 244
Study: 26546142

Group type: EXPERIMENTAL
Intervention: Ranolazine added to standard-of-care (SoC)
Number of subjects: 10000

Group type: COMPARATOR
Intervention: Standard-of-care (SoC) alone
Number of subjects: 10000
Study: 23609167

Group type: EXPERIMENTAL
Intervention: HCC patients with cirrhosis
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: HCC patients with chronic hepatitis B
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: HCC patients with chronic hepatitis C
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: HCC patients with alcohol use
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: HCC patients with smoking
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: HCC patients with diabetes (subgroup with no traditional risk factors)
Number of subjects: 150
Study: 21087288

Group type: EXPERIMENTAL
Intervention: NETE-8 (norethisterone enanthate 200 mg every 8 weeks plus testosterone undecanoate 1000 mg)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: NETE-6/12 (norethisterone enanthate 200 mg every 6 weeks for 12 weeks and then every 12 weeks plus testosterone undecanoate 1000 mg)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: NETE-6/12/0 (norethisterone enanthate 200 mg every 6 weeks for 12 weeks and then testosterone undecanoate plus placebo every 12 weeks)
Number of subjects: 50

Group type: COMPARATOR
Intervention: NETE-0/0 (placebo)
Number of subjects: 50
Study: 19654570

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg b.i.d.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 16995976

Group type: EXPERIMENTAL
Intervention: Combined non-biological artificial liver treatment
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group (no combined non-biological artificial liver treatment)
Number of subjects: 103
Study: 15591335

Group type: EXPERIMENTAL
Intervention: RT-PCR assay of 21 genes
Number of subjects: 668

Group type: EXPERIMENTAL
Intervention: Recurrence score from RT-PCR assay
Number of subjects: 668
Study: 11389408

Group type: EXPERIMENTAL
Intervention: Specific exercise group
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 39
Study: 9024169

Group type: EXPERIMENTAL
Intervention: Triazolam (0.5 mg) after rifampin (600 mg once daily for 5 days)
Number of subjects: 10
Study: 8101045

Group type: EXPERIMENTAL
Intervention: Flumazenil administered intravenously in small, incremental doses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 0
Study: 2874278

Group type: EXPERIMENTAL
Intervention: Botulinum-A toxin
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 30545338

Group type: EXPERIMENTAL
Intervention: Tamsulosin
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study: 26494727

Group type: EXPERIMENTAL
Intervention: Multivitamin supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lower mean corpuscular volumes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher birth weights
Number of subjects: 0
Study: 24956863

Group type: EXPERIMENTAL
Intervention: Xihuangwan (XHW)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (surgical treatment + chemotherapy regimen PTX + EPI + CTX)
Number of subjects: 84
Study: 21131072

Group type: EXPERIMENTAL
Intervention: PCI with initial thrombus aspiration (IT)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: PCI with tirofiban infusion (TI)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: PCI with both treatments (IT+TI)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard PCI
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Thrombus aspiration (IT)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Tirofiban infusion (TI)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Thrombus aspiration with tirofiban (IT+TI)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 100
Study: 20518784

Group type: EXPERIMENTAL
Intervention: BF-200 ALA
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo PDT
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Aktilite CL128
Number of subjects: 122
Study: 18693409

Group type: EXPERIMENTAL
Intervention: Crenotherapy
Number of subjects: 237

Group type: COMPARATOR
Intervention: Paroxetine
Number of subjects: 237
Study: 16324409

Group type: EXPERIMENTAL
Intervention: Glucosamine hydrochloride (GH) 1440 mg/day for 4 weeks
Number of subjects: 142

Group type: COMPARATOR
Intervention: Glucosamine sulfate (GS) 1500 mg/day for 4 weeks
Number of subjects: 142
Study: 12934980

Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg/day increased to 60 mg/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Citalopram (continued treatment)
Number of subjects: 24
Study: 10848459

Group type: EXPERIMENTAL
Intervention: Beat Health (civil remedy program)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control treatment (patrol response)
Number of subjects: 100
Study: 8848916

Group type: EXPERIMENTAL
Intervention: Intrathecal (0.4 mg) and intramuscular (4 mg) morphine (IT‐IM‐group)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intrathecal (0.4 mg) morphine and intramuscular saline (IT‐group)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups (IT‐IM and IT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intrathecal (0.4 mg) morphine (IT‐group)
Number of subjects: 20
Study: 1325325

Group type: COMPARATOR
Intervention: Low calcium diet
Number of subjects: 10

Group type: COMPARATOR
Intervention: High calcium diet
Number of subjects: 10

Group type: COMPARATOR
Intervention: Water restriction
Number of subjects: 10

Group type: COMPARATOR
Intervention: Water diuresis
Number of subjects: 10
Study: 6438851

Group type: EXPERIMENTAL
Intervention: Ifosfamide (IF) at 1.8 g/m2 days 1‐5 q 4 weeks with Mesna (0.36 g/m2 i.v. or 0.72 g/m2 orally) given after each IF injection.
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Mesna uroprotection
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Ifosfamide (IF)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Ifosfamide + Mesna combination
Number of subjects: 36
Study: 30967589

Group type: EXPERIMENTAL
Intervention: Animal-assisted therapy (AAT)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control therapy sessions
Number of subjects: 19
Study: 30186869

Group type: EXPERIMENTAL
Intervention: Boer formula
Number of subjects: 55

Group type: COMPARATOR
Intervention: James formula
Number of subjects: 55
Study: 26803431

Group type: EXPERIMENTAL
Intervention: Aerobic interval training (AIT) at 85-90% of peak heart rate three times/week for 12 weeks
Number of subjects: 70

Group type: COMPARATOR
Intervention: Low energy diet (LED, 800-1000 kcal/day) for 8-10 weeks followed by 2-4 weeks' weight maintenance diet
Number of subjects: 70
Study: 24472270

Group type: EXPERIMENTAL
Intervention: 5° laterally elevated wedged insoles (group A)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Neutrally wedged insoles (group B)
Number of subjects: 118
Study: 22676937

Group type: EXPERIMENTAL
Intervention: Post-conditioning
Number of subjects: 50
Study: 20661086

Group type: EXPERIMENTAL
Intervention: MBAC/AWBF
Number of subjects: 191

Group type: COMPARATOR
Intervention: N-MBAC/AWBF
Number of subjects: 191
Study: 17445128

Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Immediate cord clamping (Control)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Delayed cord clamping (DCC) and Immediate cord clamping (Control)
Number of subjects: 91
Study: 15543327

Group type: EXPERIMENTAL
Intervention: Epidural anesthesia (EA) and general anesthesia (GA) combined (Group EA/GA)
Number of subjects: 19

Group type: COMPARATOR
Intervention: General anesthesia (GA) alone (Group GA)
Number of subjects: 19
Study: 12039990

Group type: EXPERIMENTAL
Intervention: Active vitamin D (0.25 microg/d) plus calcium (1000 mg/d)
Number of subjects: 111

Group type: COMPARATOR
Intervention: No treatment (NoT group)
Number of subjects: 111
Study: 9682957

Group type: EXPERIMENTAL
Intervention: Surface treated catheters (SPI-ARGENT, Spire Corporation, Bedford, MA)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Untreated catheters
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Surface treated catheters
Number of subjects: 122
Study: 7981510

Group type: EXPERIMENTAL
Intervention: Superparamagnetic iron oxide (SHU 555 A) at doses of 5, 10, 20, and 40 mumol/kg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Superparamagnetic iron oxide (SHU 555 A)
Number of subjects: 32
Study: 2689345

Group type: EXPERIMENTAL
Intervention: Aztreonam (1 g i.v. bolus t.i.d. for a mean of 8.2 days)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Cefuroxime (1.5 g i.v. bolus t.i.d. for a mean of 8.2 days)
Number of subjects: 62
Study: 31187152

Group type: COMPARATOR
Intervention: IV THC (0.05 mg/kg)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Tolcapone (200 mg) followed by IV THC
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Tolcapone (200 mg)
Number of subjects: 74
Study: 28594714

Group type: EXPERIMENTAL
Intervention: Immediate surgery (arm A)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Standard radiochemotherapy (Cap 50: 50 Gy irradiation and 1600 mg/m oral capecitabine daily) plus surgery (arm B)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Cap 50 (arm C)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Intensive radiochemotherapy (Cap 60, 60 Gy irradiation, arm D)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Cap 50 and Cap 60 (arms C and D)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Circumferential resection margin ≤1 rates
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Transformation from positive to negative circumferential resection margin
Number of subjects: 206
Study: 25268043

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Etomidate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thiopental
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 24075767

Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with nuts
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with olive oil
Number of subjects: 169
Study: 21350408

Group type: EXPERIMENTAL
Intervention: Cytoflavin (infusion solution) prescribed in the first 2‐4 hours after delivery to 61 newborns
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (59 newborns who did not receive the drug)
Number of subjects: 120
Study: 19298567

Group type: EXPERIMENTAL
Intervention: Baseline LBBB present in 246 (2.6%) patients
Number of subjects: 9541

Group type: EXPERIMENTAL
Intervention: Baseline RBBB present in 428 (4.5%) patients
Number of subjects: 9541
Study: 17253066

Group type: EXPERIMENTAL
Intervention: Intrarectal lidocaine gel (10cc)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Periprostatic lidocaine injection (1% in 10cc)
Number of subjects: 44
Study: 14587264

Group type: EXPERIMENTAL
Intervention: Clopidogrel 300 mg loading dose given at least 6 hours before PCI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg once daily after PCI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Doubling the loading dose of clopidogrel if intervention must be undertaken sooner
Number of subjects: 0
Study: 10893283

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus vinorelbine (G + V)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Vinorelbine alone (V)
Number of subjects: 120